Generic Name and Formulations:
Tedizolid phosphate 200mg; tabs.
Merck & Co., Inc.
Indications for SIVEXTRO:
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
≥18yrs: 200mg once daily for 6 days.
<18yrs: not established.
Not adequately evaluated in patients with neutropenia (ANC <1000 cells/mm3); consider alternate therapies. Risk of C. difficile-associated diarrhea; discontinue if suspected or confirmed. Pregnancy (Cat.C). Nursing mothers.
Tabs: May potentiate oral BCRP substrates; consider interrupting co-administered substrates esp. those with narrow therapeutic index (eg, methotrexate, topotecan); monitor if coadministration (including rosuvastatin) is necessary.
Nausea, headache, diarrhea, vomiting, dizziness.
Tabs—6 (blister pack), 30; single-use vials—10
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Suicide Attempt Risk Among LGB Populations Higher Than Previously Estimated
- Residents Should Take Advantage of Paid Time Off
- Prevalence of Alzheimer Disease, Related Dementia Set to Double
- Forms of Childhood Adversity Related to First-Episode Psychosis Outcomes
- Assortative Mating Among Bipolar Patients in the United States Increases Risk for Illness in Offspring